Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Propranolol treatment of infantile hemangiomas: anticipatory guidance for parents and caretakers. Pediatr Dermatol 2013 Jan-Feb;30(1):155-9 PMID: 23316721 PMCID: PMC4786439

Pubmed ID

23316721

DOI

10.1111/pde.12022

Abstract

Infantile hemangiomas (IH) are benign tumors of endothelial-like cells. Occurring in 4.5% of children, they are the most common tumor of childhood. The great majority of patients with IH will not need treatment, but 10% require systemic treatment. Many treatments have been described for the treatment of IH, but the Food and Drug Administration has not approved any. Over the last decade, numerous reports of successful treatment of IH with propranolol have been published. Despite its widespread use, little is known regarding the proper dosing, safety monitoring, and during of treatment or long-term outcomes for propranolol treatment of IH. Given its potential side effects, detailed education regarding proper administration of the medication as well as warning signs to watch for is necessary for parents and caretakers. Herein, we provide a parental handout that practitioners can individually tailor for use in their clinics when educating parents and caretakers about the use of propranolol for IH. Updates will also need to be made as more is learned regarding the optimal dosing and safety monitoring when using propranolol for this indication.

Author List

Martin K, Blei F, Chamlin SL, Chiu YE, Frieden IJ, Frommelt PC, Garzon MC, Kwon EK, MacLellan-Tobert S, Mancini AJ, Seefeldt M, Sidbury R, Siegel DH, Drolet BA, Boucek RJ

Authors

Yvonne E. Chiu MD Associate Professor in the Dermatology department at Medical College of Wisconsin
Peter C. Frommelt MD Professor in the Pediatrics department at Medical College of Wisconsin
Dawn Siegel MD Associate Professor in the Dermatology department at Medical College of Wisconsin




Scopus

2-s2.0-84872359114   17 Citations

MESH terms used to index this publication - Major topics in bold

Caregivers
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Guidelines as Topic
Hemangioma, Capillary
Humans
Infant
Infant, Newborn
Male
Neoplastic Syndromes, Hereditary
Parents
Propranolol
Risk Assessment
Skin Neoplasms
Treatment Outcome
jenkins-FCD Prod-321 98992d628744e349846c2f62ac68f241d7e1ea70